BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kontoghiorghe CN, Kolnagou A, Kontoghiorghes GJ. Potential clinical applications of chelating drugs in diseases targeting transferrin-bound iron and other metals. Expert Opin Investig Drugs. 2013;22:591-618. [PMID: 23586878 DOI: 10.1517/13543784.2013.787408] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Kontoghiorghes GJ, Kontoghiorghe CN. Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases. Cells 2020;9:E1456. [PMID: 32545424 DOI: 10.3390/cells9061456] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
2 Timoshnikov V, Kobzeva T, Polyakov N, Kontoghiorghes G. Inhibition of Fe2+- and Fe3+- induced hydroxyl radical production by the iron-chelating drug deferiprone. Free Radical Biology and Medicine 2015;78:118-22. [DOI: 10.1016/j.freeradbiomed.2014.10.513] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
3 Kontoghiorghe CN, Kolnagou A, Kontoghiorghes GJ. Phytochelators Intended for Clinical Use in Iron Overload, Other Diseases of Iron Imbalance and Free Radical Pathology. Molecules 2015;20:20841-72. [PMID: 26610453 DOI: 10.3390/molecules201119725] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
4 Maher P, Kontoghiorghes GJ. Characterization of the Neuroprotective Potential of Derivatives of the Iron Chelating Drug Deferiprone. Neurochem Res 2015;40:609-20. [DOI: 10.1007/s11064-014-1508-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
5 Kontoghiorghes GJ, Kolnagou A, Demetriou T, Neocleous M, Kontoghiorghe CN. New Era in the Treatment of Iron Deficiency Anaemia Using Trimaltol Iron and Other Lipophilic Iron Chelator Complexes: Historical Perspectives of Discovery and Future Applications. Int J Mol Sci 2021;22:5546. [PMID: 34074010 DOI: 10.3390/ijms22115546] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Rao SS, Adlard PA. Untangling Tau and Iron: Exploring the Interaction Between Iron and Tau in Neurodegeneration. Front Mol Neurosci 2018;11:276. [PMID: 30174587 DOI: 10.3389/fnmol.2018.00276] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
7 Kontoghiorghes GJ. Advances on Chelation and Chelator Metal Complexes in Medicine. Int J Mol Sci 2020;21:E2499. [PMID: 32260293 DOI: 10.3390/ijms21072499] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
8 Merkel DG, Nagler A. Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes. Expert Rev Anticancer Ther 2014;14:817-29. [PMID: 24641787 DOI: 10.1586/14737140.2014.896208] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
9 Kolnagou A, Kontoghiorghe CN, Kontoghiorghes GJ. Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases. World J Methodol 2014; 4(4): 197-218 [PMID: 25541601 DOI: 10.5662/wjm.v4.i4.197] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
10 Kontoghiorghes GJ, Kontoghiorghe CN. Prospects for the introduction of targeted antioxidant drugs for the prevention and treatment of diseases related to free radical pathology. Expert Opinion on Investigational Drugs 2019;28:593-603. [DOI: 10.1080/13543784.2019.1631284] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
11 Kontoghiorghes GJ. Deferiprone: A Forty-Year-Old Multi-Targeting Drug with Possible Activity against COVID-19 and Diseases of Similar Symptomatology. Int J Mol Sci 2022;23:6735. [PMID: 35743183 DOI: 10.3390/ijms23126735] [Reference Citation Analysis]
12 Asmari M, Abdel-megied AM, Michalcová L, Glatz Z, El Deeb S. Analytical approaches for the determination of deferiprone and its iron (III) complex: Investigation of binding affinity based on liquid chromatography-mass spectrometry (LC-ESI/MS) and capillary electrophoresis-frontal analysis (CE/FA). Microchemical Journal 2020;154:104556. [DOI: 10.1016/j.microc.2019.104556] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Rao SS, Portbury SD, Lago L, McColl G, Finkelstein DI, Bush AI, Adlard PA. The Iron Chelator Deferiprone Improves the Phenotype in a Mouse Model of Tauopathy. J Alzheimers Dis 2020;77:753-71. [PMID: 32741833 DOI: 10.3233/JAD-200551] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
14 Kontoghiorghes GJ, Kolnagou A, Kontoghiorghe CN, Mourouzidis L, Timoshnikov VA, Polyakov NE. Trying to Solve the Puzzle of the Interaction of Ascorbic Acid and Iron: Redox, Chelation and Therapeutic Implications. Medicines (Basel) 2020;7:E45. [PMID: 32751493 DOI: 10.3390/medicines7080045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
15 Kontoghiorghe CN, Kontoghiorghes GJ. New developments and controversies in iron metabolism and iron chelation therapy. World J Methodol 2016; 6(1): 1-19 [PMID: 27019793 DOI: 10.5662/wjm.v6.i1.1] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
16 Pretorius E, Akeredolu OO, Soma P, Kell DB. Major involvement of bacterial components in rheumatoid arthritis and its accompanying oxidative stress, systemic inflammation and hypercoagulability. Exp Biol Med (Maywood) 2017;242:355-73. [PMID: 27889698 DOI: 10.1177/1535370216681549] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 8.0] [Reference Citation Analysis]
17 Asmari M, Michalcová L, Alhazmi HA, Glatz Z, El Deeb S. Investigation of deferiprone binding to different essential metal ions using microscale thermophoresis and electrospray ionization mass spectrometry. Microchemical Journal 2018;137:98-104. [DOI: 10.1016/j.microc.2017.10.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
18 Kontoghiorghe CN, Kontoghiorghes GJ. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes. Drug Des Devel Ther 2016;10:465-81. [PMID: 26893541 DOI: 10.2147/DDDT.S79458] [Cited by in Crossref: 49] [Cited by in F6Publishing: 33] [Article Influence: 8.2] [Reference Citation Analysis]